Rudolph, Dorothea

CREB regulates hepatic gluconeogenesis through the coactivator PGC-1

Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001) · Nature

Metabolism, Diabetes, and CancerPeroxisome Proliferator-Activated Receptors

Cited by 1,440

Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth

Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 534

Severe liver degeneration and lack of NF-κ B activation in NEMO/IKKγ-deficient mice

Rudolph, D., Yeh, W.-C., Wakeham, A., Rudolph, B., Nallainathan, D., Potter, J., Elia, A. J., & Mak, T. W. (2000) · Genes & Development

NF-κB Signaling PathwaysImmune Response and Inflammation

Cited by 479

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 207

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS G12C Inhibitor

Bröker, J., Waterson, A. G., Smethurst, C., Kessler, D., Böttcher, J., Mayer, M., Gmaschitz, G., Phan, J., Little, A., Abbott, J. R., et al. (2022) · Journal of Medicinal Chemistry

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 96

BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models

Hao, X., Bahia, R. K., Cseh, O., Bozek, D. A., Blake, S., Rinnenthal, J., Weyer-Czernilofsky, U., Rudolph, D., & Artee Luchman, H. (2023) · Neuro-Oncology

Cancer-related Molecular PathwaysGlioma Diagnosis and Treatment

Cited by 34

Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Savarese, F., Gollner, A., Rudolph, D., Lipp, J., Popow, J., Hofmann, M. H., Arnhof, H., Rinnenthal, J., Trapani, F., Gmachl, M., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 25

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan.

Hofmann, M. H., Lu, H., Duenzinger, U., Gerlach, D., Trapani, F., Machado, A. A., Daniele, J. R., Waizenegger, I., Gmachl, M., Rudolph, D., et al. (2021) · Cancer Research

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 20

Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules

Gollner, A., Rudolph, D., Weyer-Czernilofsky, U., Baumgartinger, R., Jung, P., Weinstabl, H., Ramharter, J., Grempler, R., Quant, J., Rinnenthal, J., et al. (2024) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysCancer Mechanisms and Therapy

Cited by 18